Paget's disease of the breast natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 21: Line 21:
*In another study, the mean 10-year [[survival rate]] was estimated at 47% in cases with positive lymph nodes and 93% in those with negative [[lymph nodes]].
*In another study, the mean 10-year [[survival rate]] was estimated at 47% in cases with positive lymph nodes and 93% in those with negative [[lymph nodes]].
*When the [[disease]] occurs in [[males]], the [[prognosis]] is poor, with an average 5-year [[Survival analysis|survival]] rate of 20-30%.
*When the [[disease]] occurs in [[males]], the [[prognosis]] is poor, with an average 5-year [[Survival analysis|survival]] rate of 20-30%.
*Patients with Paget disease concomitant infiltrating duct carcinoma (PD‐IDC)had the worst prognosis with 5‐year survival rate = 84.1%.
*Patients with Paget disease concomitant infiltrating [[duct carcinoma]] (PD‐IDC)had the worst prognosis with 5‐year survival rate = 84.1%.
*The Paget disease concomitant [[Ductal carcinoma|intraductal carcinoma]] (PD‐DCIS) had the best [[prognosis]] with 5‐year [[survival]] rate = 97.5%.
*The Paget disease concomitant [[DICS|intraductal carcinoma]] (PD‐DCIS) had the best [[prognosis]] with 5‐year [[survival]] rate = 97.5%.
*Among [[patients]] with Paget disease those who are married have a better [[prognosis]] than who were not.  
*Among [[patients]] with Paget disease those who are married have a better [[prognosis]] than who were not.  
*Marital status is said to be associated with the [[hormone receptor]] status in patients with PD‐IDC.<ref name="pmid29722170">{{cite journal |vauthors=Zhao Y, Sun HF, Chen MT, Gao SP, Li LD, Jiang HL, Jin W |title=Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population-based study |journal=Cancer Med |volume=7 |issue=6 |pages=2307–2318 |date=June 2018 |pmid=29722170 |pmc=6010794 |doi=10.1002/cam4.1475 |url=}}</ref>
*Marital status is said to be associated with the [[hormone receptor]] status in patients with PD‐IDC.<ref name="pmid29722170">{{cite journal |vauthors=Zhao Y, Sun HF, Chen MT, Gao SP, Li LD, Jiang HL, Jin W |title=Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population-based study |journal=Cancer Med |volume=7 |issue=6 |pages=2307–2318 |date=June 2018 |pmid=29722170 |pmc=6010794 |doi=10.1002/cam4.1475 |url=}}</ref>

Revision as of 17:35, 14 March 2019

Paget's disease of the breast Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paget's disease of the breast from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Biopsy

Ultrasonography

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Paget's disease of the breast natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paget's disease of the breast natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paget's disease of the breast natural history, complications and prognosis

CDC on Paget's disease of the breast natural history, complications and prognosis

Paget's disease of the breast natural history, complications and prognosis in the news

Blogs on Paget's disease of the breast natural history, complications and prognosis

Directions to Hospitals Treating Paget's disease of the breast

Risk calculators and risk factors for Paget's disease of the breast natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Overview

The prognosis for people with Paget's disease of the breast is primarily determined by the underlying tumor. Unfavorable prognosis is seen in cases with palpable breast tumor, enlarged lymph nodesand in patients younger than 60 years of age. Prognosis is worse in males than in females. Mean survival was found to be 80.0 months for males and 108.2 months for females. Five-year survival rate has been reported to be 20-30% in males, compared to 30-40% in females. This has been hypothesized to be due to the small size of mammary gland in males.

Prognosis

  • The prognosis for people with Paget's disease of the breast depends on a variety of factors, and is primarily determined by the underlying tumor.
  • Some factors indicate an unfavorable prognosis, such as:[1][2]
  • Prognosis of Paget's disease is worse in males than in females.

Survival rates

References

  1. Lopes Filho, Lauro Lourival; Lopes, Ione Maria Ribeiro Soares; Lopes, Lauro Rodolpho Soares; Enokihara, Milvia M. S. S.; Michalany, Alexandre Osores; Matsunaga, Nobuo (2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–231. doi:10.1590/abd1806-4841.20153189. ISSN 1806-4841.
  2. Paget's disease of the breast. National cancer institute. http://www.cancer.gov/types/breast/paget-breast-fact-sheet
  3. . doi:10.1001/ archdermatol.2008.508. Check |doi= value (help). Missing or empty |title= (help)
  4. Leibou L, Herman O, Frand J, Kramer E, Mordechai S (January 2015). "Paget's disease of the male breast with underlying ductal carcinoma in situ". Isr. Med. Assoc. J. 17 (1): 64–5. PMID 25739183.
  5. Zhao Y, Sun HF, Chen MT, Gao SP, Li LD, Jiang HL, Jin W (June 2018). "Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population-based study". Cancer Med. 7 (6): 2307–2318. doi:10.1002/cam4.1475. PMC 6010794. PMID 29722170.